# A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke

Study · id `cardio:ct-nct05515393` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05515393](<https://clinicaltrials.gov/study/NCT05515393>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05515393

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.

## Technical summary

Registry record NCT05515393. Randomized; triple masking; primary purpose treatment. Start 2022-09-24 (actual); primary completion 2023-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 420 participants (planned count; ClinicalTrials.gov record NCT05515393, source copy `cardio:ctgov-nct05515393-2023-06-22`, retrieved 2026-10-26)
- Started: 2022-09-24 (actual) (ClinicalTrials.gov record NCT05515393, source copy `cardio:ctgov-nct05515393-2023-06-22`, retrieved 2026-10-26)
- Primary completion: 2023-12-30 (anticipated) (ClinicalTrials.gov record NCT05515393, source copy `cardio:ctgov-nct05515393-2023-06-22`, retrieved 2026-10-26)
- Completion: 2023-12-30 (anticipated) (ClinicalTrials.gov record NCT05515393, source copy `cardio:ctgov-nct05515393-2023-06-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05515393, source copy `cardio:ctgov-nct05515393-2023-06-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05515393-2023-06-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
- Acronym: XY03-EA
- Condition: Acute Ischemic Stroke
- Intervention (Drug): XY03-EA
- Intervention (Drug): XY03-EA Placebo
- Lead sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: First Affiliated Hospital, Sun Yat-Sen University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd (`cardio:org-shijiazhuang-yiling-pharmaceutical-co-ltd`)
- Registry lists this organization as a collaborator: First Affiliated Hospital, Sun Yat-Sen University (`cardio:org-first-affiliated-hospital-sun-yat-sen-university`)

## Provenance

Content hash: 90b695ab9185862d8ee4ac27c03961cf3fc0c335e0670e5ef1cc830895f08e99
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
